KAM
QNCX icon

Knightsbridge Asset Management’s Quince Therapeutics QNCX Stock Holding History

Knightsbridge Asset Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,143
Closed -$344K – 113
2023
Q2 		$344K Buy
+1,143
New +$356K 0.11% 85

Other funds holding QNCX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Knightsbridge Asset Management's QNCX Position: Q3 2023 in Review

Knightsbridge Asset Management sold out of Quince Therapeutics (QNCX) in Q3 2023, closing a stake of 1,143 shares — an estimated $344K sold.

Knightsbridge Asset Management first reported a position in QNCX in Q2 2023 and held it in 1 quarter. The position peaked at $344K in Q2 2023. 40 funds tracked by Wall St. Rank hold QNCX as of Q3 2023.

  • Knightsbridge Asset Management reported no remaining Quince Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Knightsbridge Asset Management sold 1,143 Quince Therapeutics shares in Q3 2023, an estimated $344K.
  • Knightsbridge Asset Management first reported a position in Quince Therapeutics in Q2 2023 and held it in 1 quarter.
  • Knightsbridge Asset Management's Quince Therapeutics position peaked at $344K in Q2 2023.
  • 40 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2023.

Based on Knightsbridge Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.